We have a vacancy for a Bioconjugation Scientist to join our Bioconjugation Chemistry team in Cambridge (UK). In this lab-based role you will be working as part of a team on client-facing, often short-term projects from the outset, in a fast-paced and supportive environment.

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. Working with a varied range of customers from academic groups, small biotech and big pharma and on a diverse range of drug types from antibodies, fusion proteins and bioconjugates, Abzena supports the development and manufacture of better treatments for patients. As a testimony of its outstanding expertise and quality of its services in biologics and bioconjugates early development, Abzena won the One Nucleus Award, Best R&D Service Provider Performance of the Year2024.

The Bioconjugation Group in Abzena Cambridge (UK) provides conjugation solutions to support partner antibody drug conjugate (ADC), antibody oligonucleotide conjugate (AOC) and other bioconjugate development programs. Using established conjugation chemistries and our next-generation conjugation platform ThioBridge® with access to a wide range of payloads, we design, synthesise and produce ADCs from mg to g scale to support their evaluation by our Bioassay and Analytics groups and in vivo studies partners for lead candidate selection.

UK EEO: Abzena is committed to promoting equal opportunities in employment. All our employees and any job applicants will receive equal treatment regardless of age, disability, gender reassignment, marital or civil partner status, pregnancy or maternity, race, colour, nationality, ethnic or national origin, religion or belief, sex or sexual orientation (“Protected Characteristics”).